Iridian Asset Management LLC CT Has $9.41 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Iridian Asset Management LLC CT cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,965 shares of the medical research company’s stock after selling 4,078 shares during the quarter. Charles River Laboratories International makes up 2.5% of Iridian Asset Management LLC CT’s portfolio, making the stock its 14th largest position. Iridian Asset Management LLC CT owned 0.10% of Charles River Laboratories International worth $9,408,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in shares of Charles River Laboratories International by 2.3% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 5,951 shares of the medical research company’s stock worth $1,099,000 after acquiring an additional 133 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in Charles River Laboratories International by 11.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 125,097 shares of the medical research company’s stock worth $23,093,000 after purchasing an additional 13,102 shares during the last quarter. YANKCOM Partnership acquired a new position in Charles River Laboratories International during the 4th quarter worth $92,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Charles River Laboratories International by 46.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company’s stock valued at $987,000 after buying an additional 1,679 shares during the last quarter. Finally, E. Ohman J or Asset Management AB increased its stake in shares of Charles River Laboratories International by 225.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company’s stock valued at $480,000 after buying an additional 1,800 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CRL. Redburn Atlantic assumed coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price objective for the company. TD Cowen lifted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Monday. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday. Finally, Bank of America lowered their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $200.79.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $166.32 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12 month low of $159.65 and a 12 month high of $275.00. The firm has a fifty day simple moving average of $181.32 and a 200 day simple moving average of $194.07. The stock has a market capitalization of $8.51 billion, a price-to-earnings ratio of 20.82, a PEG ratio of 6.25 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the previous year, the business earned $2.72 earnings per share. Charles River Laboratories International’s quarterly revenue was down 1.6% on a year-over-year basis. Research analysts forecast that Charles River Laboratories International, Inc. will post 10.17 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).